SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma
SARC041, is for patients who are 18 and older and have recurrent and/or metastatic dedifferentiated liposarcoma. Patients will either receive abemaciclib or a placebo when they enroll, and they will not know which drug they are receiving at the time of enrollment. A patient who experiences progression of their cancer while receiving the placebo pill will be allowed to receive abemaciclib instead. There is no specific biomarker required for eligibility for this study.